Entropy Neurodynamics Narrows Half-Year Loss and Lifts Asset Backing After Rebrand

An announcement from Tryptamine Therapeutics ( (AU:ENP) ) is now available.

Entropy Neurodynamics Limited reported a sharp increase in revenue from ordinary activities to $48,528 for the half-year to 31 December 2025, but continued to post a net loss, albeit a reduced one, of $3.43 million compared with $4.03 million a year earlier. Basic and diluted losses per share both narrowed, while net tangible assets per share improved to 0.48 cents from 0.30 cents, indicating some balance sheet strengthening despite the absence of dividends.

The results reflect the first half-year under the company’s new Entropy Neurodynamics name and ASX ticker ENP, following its rebranding from Tryptamine Therapeutics, with no changes in control of subsidiaries or new associates or joint ventures during the period. The financial statements were reviewed by auditors, and the group, which includes Canadian and U.S. entities applying IFRS Accounting Standards, continues to operate as a loss-making but asset-backed early-stage neurotherapeutics business without returning capital to shareholders.

The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.

More about Tryptamine Therapeutics

Entropy Neurodynamics Limited, formerly known as Tryptamine Therapeutics Limited, is an ASX-listed company operating in the neurotherapeutics and biotechnology space. The group includes subsidiaries in Canada and the U.S., which report under International Financial Reporting Standards, underscoring its cross-border structure and focus on developing neurological treatment assets.

Average Trading Volume: 2,348,219

Technical Sentiment Signal: Buy

Current Market Cap: A$56.49M

For a thorough assessment of ENP stock, go to TipRanks’ Stock Analysis page.